Ipsen SA (IPN)

109.70 -0.40 (-0.36%)
Real-time Data EUR Disclaimer

Ipsen SA Company Profile

Equity Type
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Contact Information
Boulogne-Billancourt,92100 France
33 1 58 33 50 00
33 1 58 33 50 01
Top Executives
Philippe Bonhomme 54 2012 Director
Marc M. P. de Garidel 65 2010 Non-Executive Chairman
Margaret A. Liu 67 2017 Independent Director
Carol Xueref 68 2012 Director
Anne Beaufour 60 2005 Director
Karen Witts 60 2022 Independent Director
Henri Beaufour 58 2005 Director
Michèle Ollier 65 2015 Director
Antoine Flochel 58 2005 Vice Chairman
David Loew 56 2020 MD, CEO & Director
Laetitia Ducroquet 44 2020 Employees Representative Director
Piet Wigerinck 59 2018 Independent Director
Naomi Binoche 48 2022 Employee Representative Director
Pascal Touchon 60 2023 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.